1. Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series
- Author
-
S. Batlle-Ferrando, X. Carreras Castañer, José-María Sánchez-González, L. Miguel-Escuder, S. Marín-Martínez, Felipe Spencer, Jorge Peraza-Nieves, N. Sabater-Cruz, C. Rocha-de-Lossada, and J. Torras
- Subjects
business.industry ,Neurotrophic keratitis ,corneal ulcer ,medicine.disease ,Nicergoline ,Ophthalmology ,Anesthesia ,Adjunctive treatment ,medicine ,Immunology and Allergy ,In patient ,Routine clinical practice ,business ,Wound healing ,Adverse effect ,medicine.drug - Abstract
PURPOSE To describe the effectiveness and safety of nicergoline in patients with epithelial corneal defect or corneal ulcer due to neurotrophic keratitis (NK). METHODS A prospective case series review was performed in 14 patients with NK who started treatment with nicergoline as an off-label prescription from January to November 2020. Patients with a epithelial defect or corneal ulcer due to NK were treated with oral nicergoline. RESULTS/SERIAL CASES Complete corneal healing was observed in 10 (71.4%) of the 14 patients after 25.6 ± 26.60 days (range 7-90) with nicergoline. In three (21.5%) patients wound healing was not achieved, and one patient (7.1%) was lost to follow-up. The mean time between diagnosis and the starting of nicergoline was 10.92 ± 8.85 days (0-28). No adverse effects of nicergoline were observed. CONCLUSION Nicergoline as an adjunctive treatment for NK showed a potential use in the healing of epithelial defect in real-life clinical practice.
- Published
- 2021
- Full Text
- View/download PDF